Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

699
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
699
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

2.5K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.5K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

2.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.3K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
1.1K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

2.1K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lack of Antidepressant Effects of Low-Voltage-Sensitive T-Type Calcium Channel Blocker Ethosuximide in a Chronic Social Defeat Stress Model: Comparison with (R)-Ketamine.

The international journal of neuropsychopharmacology·2018
Same author

Role of Inflammatory Bone Markers in the Antidepressant Actions of (R)-Ketamine in a Chronic Social Defeat Stress Model.

The international journal of neuropsychopharmacology·2018
Same author

Expression of heat shock protein HSP-70 in the retrosplenial cortex of rat brain after administration of (R,S)-ketamine and (S)-ketamine, but not (R)-ketamine.

Pharmacology, biochemistry, and behavior·2018
Same author

Is (S)-norketamine an alternative antidepressant for esketamine?

European archives of psychiatry and clinical neuroscience·2018
Same author

Author Correction: Lack of metabolism in (R)-ketamine's antidepressant actions in a chronic social defeat stress model.

Scientific reports·2018
Same author

CBL1-CIPK26-mediated phosphorylation enhances activity of the NADPH oxidase RBOHC, but is dispensable for root hair growth.

FEBS letters·2018

Related Experiment Video

Updated: Apr 28, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

31.9K

Rethinking the Treatment-Resistant Depression.

Yunfei Tan1, Kenji Hashimoto2

  • 1Department of Psychiatry, Center for Rehabilitation Medicine, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.

Advances in Experimental Medicine and Biology
|April 26, 2026
PubMed
Summary
This summary is machine-generated.

Treatment-resistant depression (TRD) is a complex condition affecting many, leading to severe outcomes. Research is exploring neurobiological markers and patient subtypes to improve diagnosis and personalize treatment for better outcomes.

Keywords:
BiomarkersIndividualized treatmentInflammationKetamineNeural regulationRefractory depression

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.0K
Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
12:19

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

200

Related Experiment Videos

Last Updated: Apr 28, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

31.9K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.0K
Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
12:19

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

200

Area of Science:

  • Neuroscience
  • Psychiatry
  • Genetics

Background:

  • Treatment-resistant depression (TRD) impacts a significant portion of major depression patients, correlating with elevated suicide risks, functional impairment, and increased healthcare utilization.
  • Current TRD definitions lack consistency, hindering accurate prevalence estimation and clinical management.
  • Differential diagnosis is complicated by overlapping symptoms with other psychiatric and neurological conditions.

Purpose of the Study:

  • To review the current understanding of TRD, including diagnostic challenges, neurobiological underpinnings, clinical manifestations, and emerging personalized treatment strategies.
  • To highlight the need for standardized diagnostic criteria and the integration of multimodal biomarkers for improved patient care.

Main Methods:

  • Literature review of neurobiological research, clinical studies, and diagnostic criteria for TRD.
  • Analysis of latent class analysis findings for TRD subtypes.
  • Discussion of biomarker-driven and response-based patient categorization.

Main Results:

  • TRD is associated with neurobiological markers such as glutamatergic dysregulation, default-mode network hyperactivity, impaired neuroplasticity, inflammation, and epigenetic changes.
  • Clinical presentation includes anhedonia, cognitive deficits, somatic complaints, and sleep disturbances.
  • Latent class analysis identified distinct TRD subtypes (anxiety-agitation, cognitive-executive dysfunction, somatic-dominant, affective-deficit) with varying treatment responses.

Conclusions:

  • Standardizing TRD definitions and integrating multimodal biomarkers are crucial for early identification and prognosis.
  • Biomarker-driven and response-based patient stratification offer pathways for personalized interventions.
  • Future research should focus on cross-cultural validation of criteria and the development of targeted therapies.